The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker’s Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours:
Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA
Omeros Corporation (NASDAQ: OMER) has submitted to the FDA its response to Complete Response Letter for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
Omeros Confirms Submission Of Response To FDA Regarding BLA For Narsoplimab In Treatment Of HSCT-TMA
Omeros Corporation (NASDAQ:OMER) today confirmed that earlier this month the company submitted to the U.S. Food and Drug Administration (FDA) its response to the Agency's Complete Response Letter (CRL) for
76 Biggest Movers From Yesterday
Gainers
Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share.
55 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
RenovoRx, Inc. (NASDAQ: RNXT) shares jumped 128% to $12.41. The company, on Tuesday evening, made a presentation on intra-arterial chemotherapy as a potential innovative treatment for pancreatic cancer.
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
Omeros’ Narsoplimab Shows Improved, Stabilized Renal Function At Three Years
Omeros Corporation (NASDAQ:OMER) announced long-term follow-up (35 months) results from the Phase 2 trial of its MASP-2 inhibitor narsoplimab in patients…
Omeros Highlights Presentation Of Data At Annual Meeting Of the American Society Of Nephrology Yesterday
First Report of Narsoplimab's Effects on Complement Activation Markers in Renal Disease Presented at the Annual Meeting of the American Society of Nephrology --
Omeros Corporation (NASDAQ:OMER) today announced that